Streetbeat News

TCBP

TC Biopharm (Holdings) Plc

https://www.tcbiopharm.com

Industry

Biotechnology

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

TC BioPharm's CEO, Bryan Kobel, will participate in a Cancer Progress Panel at the 18th Annual European Life Sciences CEO Forum, discussing HealthTech topics like AI and diagnostics.

Portfolio Pulse from

February 20, 2025 | 1:15 pm

TC BioPharm (NASDAQ: TCBP) has successfully completed dosing of Cohort A in its ACHIEVE Phase 2B clinical trial, showing favorable safety and efficacy for its TCB008 therapy in patients with relapse or refractory AML.

Portfolio Pulse from

February 13, 2025 | 1:45 pm

TC BioPharm (NASDAQ: TCBP) announced a change in its ADS ratio from 1 ADS representing 200 ordinary shares to 1 ADS representing 4,000 ordinary shares, effective February 10, 2025.

Portfolio Pulse from

February 05, 2025 | 5:15 pm

TC BioPharm (NASDAQ: TCBP) plans to start preclinical studies for its lead therapeutic TCB008 targeting H5N1, or Bird Flu. The company is seeking university partners to accelerate the process towards a Phase I study.

Portfolio Pulse from

January 15, 2025 | 1:45 pm

TC BioPharm (NASDAQ: TCBP) will present at the Sequire Investor Summit 2025, where CEO Bryan Kobel will provide a corporate overview. The event is scheduled for January 21-23, 2025, in San Juan, Puerto Rico.

Portfolio Pulse from

January 13, 2025 | 2:00 pm

TC BioPharm (NASDAQ: TCBP) announced that its American Depository Shares continue to trade on the Nasdaq Global Select Market without any interruptions. The company is a clinical-stage biotechnology firm focusing on gamma-delta T cell therapies for cancer.

Portfolio Pulse from

January 06, 2025 | 6:45 pm

TC BioPharm (NASDAQ: TCBP) is advancing negotiations with two acquisition candidates as part of its M&A strategy to expand its therapeutic platform.

Portfolio Pulse from

December 31, 2024 | 3:30 pm

TC BioPharm (NASDAQ: TCBP) has announced a 25% stock dividend, which was approved at the company's General Meeting. This move is part of the company's strategy as a clinical-stage biotechnology firm.

Portfolio Pulse from

December 30, 2024 | 3:45 pm

TC BioPharm (NASDAQ: TCBP) has completed the final dosing of 3 patients in its ACHIEVE Phase 2b clinical trial for TCB008, targeting AML and MDS/AML. No drug-related adverse events were reported, indicating a positive step in the trial's progress.

Portfolio Pulse from

December 20, 2024 | 1:45 pm

TC BioPharm (NASDAQ: TCBP) has announced a general meeting to approve a special dividend of 0.25 ADSs per 1 ADS held. This decision is pending shareholder approval.

Portfolio Pulse from

December 18, 2024 | 1:45 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.